Oasmia Pharmaceutical AB (OASM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oasmia Pharmaceutical AB (OASM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3347
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oasmia Pharmaceutical AB (Oasmia Pharmaceutical) is a pharmaceutical company that develops drugs for human and veterinary oncology. The company’s product portfolio consists of animal health products that include doxophos vet and paccal vet and human health products which include doxophos, paclical, docecal and OAS-19. Its paclical is a water-soluble formulation of paclitaxel and XR-17 is used as anti-cancer therapy for treatment of cancers such as breast cancer, lung cancer and ovarian cancer. The company develops products based on in-house research within nanotechnology and company patents. Oasmia Pharmaceutical provides services which includes organic synthesis, filling, analysis and freeze-drying, labeling and packaging. The company operates through research facility in Sweden. Oasmia Pharmaceutical is headquartered in Uppsala, Sweden.

Oasmia Pharmaceutical AB (OASM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 10
Private Equity 11
Nexttobe Acquires Additional Stake In Oasmia Pharma From Alceco International 11
Partnerships 12
Oasmia Pharma Enters into Marketing and Distribution Agreement with Hetero Drugs 12
Oasmia Pharma Enters Into Co-Marketing Agreement With Pharmasyntez For Paclical 13
Oasmia Pharma Enters Into Co-Development Agreement With Pharmasyntez 14
Equity Offering 15
Oasmia Pharma Plans to Raise up to USD25 Million in Public Offering of Securities 15
Oasmia Pharma Raises USD18.8 Million in Rights Offering of Shares 16
Oasmia Pharma Raises USD7.8 Million in Private Placement of Shares 17
Oasmia Pharma Raises USD2.2 Million in Private Placement of Shares 18
Oasmia Pharma Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering for USD10.8 Million 19
Oasmia Pharma Raises USD23.8 Million in Rights Offering of Shares 21
Oasmia Pharma Raises USD7 Million in Private Placement of Shares 23
Oasmia Pharma Completes Private Placement Of Shares For US$11 Million 24
Oasmia Pharma Completes Rights Issue Of Shares For US$19 Million 25
Debt Offering 26
Oasmia Pharma Raises USD3.1 Million in Private Placement of 8% Convertible Instruments 26
Oasmia Pharma Raises USD3.3 Million in Private Placement of Convertible Instruments 27
Oasmia Pharmaceutical AB – Key Competitors 28
Oasmia Pharmaceutical AB – Key Employees 29
Oasmia Pharmaceutical AB – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Jun 08, 2018: Oasmia Pharmaceutical Year-end report for the financial year May 1, 2017 – April 30, 2018 31
Mar 02, 2018: Oasmia Pharmaceutical: Interim report for the period May 2017 – January 2018 36
Dec 01, 2017: Oasmia Pharmaceutical Interim report for the period May – October 2017 38
Sep 01, 2017: Oasmia Pharmaceutical: Interim report for the period May – July 2017 39
Jun 08, 2017: Oasmia Pharmaceutical: Year-end report for the financial year May 1, 2016 – April 30, 2017 41
Corporate Communications 43
Oct 04, 2017: Oasmia Pharmaceutical Announces Resignation of its Chief Financial Officer 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oasmia Pharmaceutical AB, Deals By Therapy Area, 2012 to YTD 2018 8
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 10
Nexttobe Acquires Additional Stake In Oasmia Pharma From Alceco International 11
Oasmia Pharma Enters into Marketing and Distribution Agreement with Hetero Drugs 12
Oasmia Pharma Enters Into Co-Marketing Agreement With Pharmasyntez For Paclical 13
Oasmia Pharma Enters Into Co-Development Agreement With Pharmasyntez 14
Oasmia Pharma Plans to Raise up to USD25 Million in Public Offering of Securities 15
Oasmia Pharma Raises USD18.8 Million in Rights Offering of Shares 16
Oasmia Pharma Raises USD7.8 Million in Private Placement of Shares 17
Oasmia Pharma Raises USD2.2 Million in Private Placement of Shares 18
Oasmia Pharma Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering for USD10.8 Million 19
Oasmia Pharma Raises USD23.8 Million in Rights Offering of Shares 21
Oasmia Pharma Raises USD7 Million in Private Placement of Shares 23
Oasmia Pharma Completes Private Placement Of Shares For US$11 Million 24
Oasmia Pharma Completes Rights Issue Of Shares For US$19 Million 25
Oasmia Pharma Raises USD3.1 Million in Private Placement of 8% Convertible Instruments 26
Oasmia Pharma Raises USD3.3 Million in Private Placement of Convertible Instruments 27
Oasmia Pharmaceutical AB, Key Competitors 28
Oasmia Pharmaceutical AB, Key Employees 29
Oasmia Pharmaceutical AB, Subsidiaries 30

List of Figures
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Oasmia Pharmaceutical AB (OASM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cox & Kings Limited:企業の戦略・SWOT・財務分析
    Cox & Kings Limited - Strategy, SWOT and Corporate Finance Report Summary Cox & Kings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • VinaPhone Company :企業の戦略・SWOT・財務情報
    VinaPhone Company - Strategy, SWOT and Corporate Finance Report Summary VinaPhone Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Daiwa House Industry Co Ltd (1925)-エネルギー分野:企業M&A・提携分析
    Summary Daiwa House Industry Co., Ltd. (Daiwa House) is a construction service provider. The company provides diversified real estate solutions such as planning, construction, leasing, management and operation of rental, pre-existing, and new buildings; renovation and real estate agency services. It …
  • Sime Darby Bhd (SIME):電力:M&Aディール及び事業提携情報
    Summary Sime Darby Bhd (Sime Darby) is a trading and logistics company. It provides diversified products and services through its subsidiaries, affiliates, and joint ventures. The company cultivates oil palm, rubber and sugarcane; rears cattle; and produces oil and fats. It also imports, assembles, …
  • Famous Dave’s of America, Inc.:企業の戦略・SWOT・財務情報
    Famous Dave's of America, Inc. - Strategy, SWOT and Corporate Finance Report Summary Famous Dave's of America, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Spark New Zealand Ltd:企業の戦略・SWOT・財務情報
    Spark New Zealand Ltd - Strategy, SWOT and Corporate Finance Report Summary Spark New Zealand Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Valecha Engineering Ltd:戦略・SWOT・企業財務分析
    Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report Summary Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Systemax Inc.:企業の戦略・SWOT・財務情報
    Systemax Inc. - Strategy, SWOT and Corporate Finance Report Summary Systemax Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • FirstRand Limited (FSR):企業の財務・戦略的SWOT分析
    FirstRand Limited (FSR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Altin Yunus Cesme Turistik Tesisler A.S.:企業の戦略・SWOT・財務分析
    Altin Yunus Cesme Turistik Tesisler A.S. - Strategy, SWOT and Corporate Finance Report Summary Altin Yunus Cesme Turistik Tesisler A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Hess Corp (HES):石油・ガス:M&Aディール及び事業提携情報
    Summary Hess Corp (Hess) is a global independent energy company which carries out the exploration and production of crude oil and natural gas. It primarily operates in US, Denmark, the Joint Development Area of Malaysia/Thailand (JDA), and Malaysia. It offers fee-based services including gathering, …
  • Petroleo Brasileiro SA (PETR4)-石油・ガス分野:企業M&A・提携分析
    Summary Petroleo Brasileiro S.A. (Petrobras) is an integrated oil and gas company. Its major businesses include exploration and production, refining, marketing , trade and transportation of oil and gas. The company also conducts biofuel, petrochemical, natural gas, electricity and chemical-gas busin …
  • Toho Holdings Co Ltd (8129):企業の財務・戦略的SWOT分析
    Toho Holdings Co Ltd (8129) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Restalia Grupo de Eurorestauracion SL:企業の戦略・SWOT・財務分析
    Restalia Grupo de Eurorestauracion SL - Strategy, SWOT and Corporate Finance Report Summary Restalia Grupo de Eurorestauracion SL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Tanami Gold NL:企業の戦略・SWOT・財務分析
    Tanami Gold NL - Strategy, SWOT and Corporate Finance Report Summary Tanami Gold NL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Eesti Energia AS-エネルギー分野:企業M&A・提携分析
    Summary Eesti Energia AS (Eesti Energia) is an international energy company that offers energy solutions ranging from electricity, heat and fuel production to sales, customer service and ancillary energy services among others. Eesti Energia sells electricity to the Baltic retail customers and the wh …
  • Orkuveita Reykjavikur:電力:M&Aディール及び事業提携情報
    Summary Orkuveita Reykjavikur (Orkuveita) is a public utility company that provides electricity and water. The company generates and supplies electricity. It harnesses hot water from geothermal fields and supplies it for heating applications. The company also supplies cold water from its groundwater …
  • SolaCom Technologies, Inc.:企業の戦略・SWOT・財務情報
    SolaCom Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary SolaCom Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Epsilon Energy Ltd (EPS):石油・ガス:M&Aディール及び事業提携情報
    Summary Epsilon Energy Ltd (Epsilon) is an oil and gas company that provides exploration, exploitation and development of oil and gas reserves. The company provides projects such as Marcellus shale in northeast Pennsylvania, Bakken Shale and Midale Dolomite in Saskatchewan, among others. It operates …
  • Alkem Laboratories Ltd (ALKEM):製薬・医療:M&Aディール及び事業提携情報
    Summary Alkem Laboratories Ltd (Alkem) is a pharmaceutical company that develops, manufactures and markets generic and specialty pharmaceutical products. The company’s products include active pharmaceutical ingredients, generic products, branded products and nutraceuticals. Alkem provides drugs for …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆